SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Longer Patents for Increased Generic Competition in the US
2 references·16 citing·45 second hop
Longer Patents for Increased Generic Competition in the US (1996)Longer Patents for Increased Generic Comp…Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Regulation and welfare: evide…Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016)Cost-effectiveness of Tyrosin…Why Is There No Generic Insulin? Historical Origins of a Modern Problem (2015)Why Is There No Generic Insul…Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation (2011)Brand Loyalty, Generic Entry …Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation (2010)Using Market-Exclusivity Ince…Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation (2010)Brand Loyalty, Generic Entry …Pharmaceutical pricing policies in a global market (2008)Pharmaceutical pricing polici…Entry and competition in generic biologics (2007)Entry and competition in gene…Price Competition in Pharmaceuticals: The Case of Anti‐infectives (2004)Price Competition in Pharmace…Dynamic competition in pharmaceuticals (2004)Dynamic competition in pharma…Are the Economics of Pharmaceutical Research and Development Changing? (2004)Are the Economics of Pharmace…The Dual Effects of Intellectual Property Regulations: Within‐ and Between‐Patent Competition in the U.S. Pharmaceuticals Industry (2002)The Dual Effects of Intellect…Generic take-up in the pharmaceutical market following patent expiry (2000)Generic take-up in the pharma…Effective patent life in pharmaceuticals (2000)Effective patent life in phar…Chapter 25 The pharmaceutical industry (2000)Chapter 25 The pharmaceutical…Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions (1997)Pharmacy benefit management, …Industrial Market Structure and Economic Performance. (1971)Product differentiation advantages of pioneering brands (1980)Generic Entry and the Pricing of Pharmaceuticals (1997)Uncertainty and Learning in Pharmaceutical Demand (2005)Killer Acquisitions (2020)Are there potential problems with generic substitution of antiepileptic drugs? (2006)Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point (2008)The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review (2018)The Evolution of Supply and Demand in Markets for Generic Drugs (2021)Patents and Innovation: An Empirical Study (1986)Optimal Patent Length and Breadth (1990)The Distribution of Sales Revenues from Pharmaceutical Innovation (2000)Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Entry Deterrence in the Ready-to-Eat Breakfast Cereal Industry (1978)Handbook of Industrial Organization (1989)Entry and Competition in Concentrated Markets (1991)Pharmaceutical Prices under Regulation: Tiered Co-payments and Reference Pricing in Germany (2012)Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs (2013)Returns to R&D on new drug introductions in the 1980s (1994)The Managed Health Care Handbook (1998)Economic Evaluations of Healthcare Programmes and Decision Making (2005)Providing Prescription Drug Coverage to the Elderly: America's Experiment with Medicare Part D (2008)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)How Valuable is Patent Protection? Estimates by Technology Field (1998)Generic Entry, Reformulations and Promotion of SSRIs in the US (2008)Contemporary generic market in Japan – key conditions to successful evolution (2014)Cost-Effectiveness in Health and Medicine (1996)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The Economics of Innovation and Intellectual Property (2024)Automobile Prices in Market Equilibrium (1995)The Regulation of Entry (2000)Discrete Choice Methods with Simulation (2003)THE WELFARE IMPACT OF PARALLEL IMPORTS: A STRUCTURAL APPROACH APPLIED TO THE GERMAN MARKET FOR ORAL ANTI‐DIABETICS (2014)Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry (2017)What is the impact of intellectual property rules on access to medicines? A systematic review (2022)Capital-Market Imperfections and Investment (1997)The price of innovation: new estimates of drug development costs (2003)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Measuring Disparities in Health Status and in Access and Use of Health Care in OECD Countries (2009)Discounts and rebates granted to public payers for medicines in European countries. (2012)Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries (2014)
this work references cited by second hop

References

  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited

Cited by

  • 2016Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States127 cited
  • 2016Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry124 cited
  • 2004Price Competition in Pharmaceuticals: The Case of Anti‐infectives118 cited
  • 2008Pharmaceutical pricing policies in a global market107 cited
  • 1997Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions94 cited
  • 2000Generic take-up in the pharmaceutical market following patent expiry92 cited
  • 2010Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation92 cited
  • 2000Effective patent life in pharmaceuticals91 cited
  • 2011Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation91 cited
  • 2004Are the Economics of Pharmaceutical Research and Development Changing?88 cited
  • 2002The Dual Effects of Intellectual Property Regulations: Within‐ and Between‐Patent Competition in the U.S. Pharmaceuticals Industry86 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2004Dynamic competition in pharmaceuticals85 cited
  • 2015Why Is There No Generic Insulin? Historical Origins of a Modern Problem81 cited
  • 2000Chapter 25 The pharmaceutical industry76 cited
  • 2010Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation70 cited
  • 2007Entry and competition in generic biologics67 cited